In a report released on April 15, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s shares closed yesterday at $67.34.
Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Boston Scientific, and Abbott Labs. According to TipRanks, Singh Chadha has an average return of -0.4% and a 42.05% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Axonics Modulation Technologies with a $71.00 average price target.
Based on Axonics Modulation Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $93.1 million and a net profit of $3.93 million. In comparison, last year the company earned a revenue of $70.38 million and had a GAAP net loss of $16.25 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axonics Modulation Technologies (AXNX) Company Description:
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.
Read More on AXNX:
